BMO Capital Markets analyst Jim Birchenough commented that Ariad has “significant value” to be realized from Iclusig. Birchenough raised his rating from Market Perform to Outperform and increased the price target from $8.00 to $14.00. Ariad told BMO that “all options, including partnership and M&A” remain on the table. The analyst added that commercializing Iclusig would require additional funding, to expand the drug beyond the narrow label.
Sentiment: Strong Buy
Even if the don't sell alot of google glass, the little they do sell will give a big boost to HIMX, but most importantly, HIMX has a solid and growing business outside of google glass.
Sierra is all over the web and as such, they are easy to track. With that said, show me one situation where they were accurate.
Sorry to bust your bubble, this site is a scam and has zero creditability.
No need to worry with ARIA. Forget the day to day volatility, buy and hold.
As an observation, a few weeks ago, the news broke on a Friday that the EU will allow Iclusig to remain on the market and as a result the stock flew, however the following monday it performed even better.
Maybe it'll move higher Monday, I don't know but i like that fact that the final EU decision is looming and the relaunch is a few weeks away, and the resumption of trials are soon to be announced.
This is a very promising CANCER drug the was approved by the FDA (TWICE), doubt that the FDA will want to look incompetent again.
The fact that while Iclusic was off the market there wasn't any uptick in volume of any competing speaks volume, the fact that Iclusig was re-approved in such a short time speaks volume. I can go on and on.
BUY AND HOLD AND FORGET THE NOISE.
One can conclude that the end result of Iclusig being pulled from the market was an over reaction by the FDA which has resulted in the great buying opportunity. Thank you FDA . I wonder if any big Pharma is thinking the same thing. After all Iclusig is the cancer drug of choice by doctors and patients. We shall see but either way, up we go!
The change in label is not new info for anyone in the medical field. This is nothing new. Ariad cancer drug is back on the market and the stock is going back to where it was. What will pfizer do?
Maybe you want the price to drop so you can buy more. Not going to happen.
Maybe you want the price to drop so you can cover. Not going to happen.
Hopefully the SP is stable on Monday so you may buy or cover before big pharma realizes that they should buy ARIAD now before the SP climbs to far north.
THE CHANGE IN LABEL IS NOT NEW INFO FOR ANYONE IN THE MEDICAL FIELD. THIS IS NOTHING NEW. ARIAD CANCER DRUG IS BACK ON THE MARKET AND THE STOCK IS GOING BACK TO WHERE IT WAS. What will Pfizer do?
Next try will kill the shorts.